Rad140 Capsules (15mg) 60 Count

Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use

Manufacturer: RiboCore

Availability: In stock

SKU: RC-RAD140-CAPSULES-15MG

Old price: $119.00

Price: $99.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
CAS Number	1182367-47-0
Molecular Weight	393.83 Da

Mechanism of Action

RAD 140 demonstrates high AR affinity with Ki = 7 nM (superior to testosterone at 29 nM and comparable to DHT at 10 nM). Shows excellent selectivity over other steroid hormone receptors-nearest off target is progesterone receptor (IC₅₀ = 750 nM vs 0.2 nM for progesterone). Functions as tissue selective mixed agonist/partial AR agonist with demonstrated activity in muscle and bone tissue while lack

Research Applications

Androgen receptor (AR) binding affinity and selectivity profiling
Tissue-selective AR agonism and partial agonist mechanism research
SARM structure-activity relationship (SAR) and drug design studies
Steroid hormone receptor selectivity and off-target profiling
Anabolic vs androgenic tissue response differentiation research
Comparative AR ligand efficacy in hormone-sensitive cancer models